Company Overview

Finch Therapeutics Group, Inc. (formerly Nasdaq-listed under the ticker FNCH and later quoted over-the-counter as FNCHQ) is a biotechnology company focused on the development of microbiome-based therapeutics intended to treat serious and chronic diseases. The company historically operated within the biopharmaceutical and microbiome therapeutics industries, with research centered on the therapeutic use of human gut microbiota to address conditions associated with dysbiosis. Finch’s primary programs included investigational therapies for recurrent Clostridioides difficile infection (CDI), autism spectrum disorder-related gastrointestinal symptoms, and inflammatory or immune-mediated conditions.

The company evolved through a series of mergers and strategic restructurings tied to the emerging microbiome therapeutics sector. Finch Therapeutics was formed through the combination of Finch Therapeutics, Inc. and Crestovo Holdings LLC, the parent company of OpenBiome. Its strategic positioning was based on proprietary microbiome manufacturing capabilities, donor-screening infrastructure, and intellectual property related to microbial therapeutics. Public filings and corporate disclosures indicate that the company experienced substantial operational and financial challenges following clinical setbacks, regulatory developments, and reduced capital availability, leading to workforce reductions, asset sales, and restructuring activities.

Business Operations

Finch historically generated value through the research, development, and potential commercialization of microbiome therapeutics. Its core operating activities included microbiome drug discovery, donor-derived biological material processing, manufacturing, and clinical development. The company’s lead assets included CP101, an orally administered full-spectrum microbiota product candidate for recurrent CDI, and earlier-stage microbiome programs developed through internal research and external collaborations. Revenue sources were limited and primarily associated with collaboration agreements, licensing arrangements, and research partnerships rather than commercial product sales.

The company operated primarily in the United States, with research, clinical, and manufacturing activities centered domestically. Finch controlled microbiome-related processing and manufacturing capabilities that were considered strategically important within the field of live biotherapeutic products. The company also maintained relationships with academic institutions and healthcare organizations connected to microbiome science and donor material sourcing. Public disclosures identified OpenBiome-related infrastructure and microbiota banking expertise as notable operational assets during the company’s active development phase.

Strategic Position & Investments

Finch’s strategic direction focused on advancing orally administered microbiome therapeutics through clinical development while leveraging proprietary manufacturing and donor-screening systems. The company pursued growth through internal R&D, licensing arrangements, and intellectual property expansion in the microbiome therapeutics field. Its development strategy emphasized full-spectrum microbiota therapeutics intended to restore microbial diversity rather than targeting single bacterial strains.

The company completed multiple strategic transactions and restructuring initiatives during its operating history. These included the merger involving Crestovo Holdings LLC, collaborations related to microbiome intellectual property, and subsequent cost-reduction measures following adverse clinical and financial developments. Public filings indicate that Finch explored strategic alternatives, including asset monetization and operational restructuring, amid liquidity pressures. Data concerning long-term standalone operations became increasingly limited after restructuring activities and over-the-counter market quotation status changes. Data inconclusive based on available public sources regarding the company’s current active development pipeline beyond disclosed restructuring actions.

Geographic Footprint

Finch Therapeutics’ operational footprint was concentrated primarily in the United States, where the company maintained headquarters, laboratory operations, and clinical development activities. The company’s headquarters were located in Massachusetts, positioning it within the broader biotechnology ecosystem of the Boston-Cambridge life sciences market. Clinical activities and partnerships were also tied to U.S.-based healthcare institutions and research organizations.

Although the company’s direct commercial presence outside the United States was limited, its scientific and intellectual property activities participated in the broader global microbiome therapeutics market. Finch’s research and development efforts were relevant to international pharmaceutical and biotechnology sectors focused on live biotherapeutic products, gastrointestinal disease treatment, and microbiome modulation technologies. Publicly available disclosures do not indicate a substantial independent operating infrastructure outside North America.

Leadership & Governance

Finch Therapeutics was founded by individuals associated with microbiome research and clinical translation initiatives, including leaders connected to the development of fecal microbiota transplantation and microbiome therapeutics. Corporate governance and leadership evolved significantly through mergers, executive transitions, and restructuring periods. Strategic leadership emphasized the advancement of regulated microbiome therapeutics using pharmaceutical development standards and scalable manufacturing systems.

Key executives and leadership figures identified in company filings and public disclosures included:

• Mark Smith, MD, PhD – Co-Founder and former Chief Executive Officer
• Kevin Rakin – Former Chief Executive Officer and Executive Chairman
• Daina Graybosch, MD – Former Chief Medical Officer
• Matt Minter – Former President and Chief Financial Officer
• George Vlahakis – Former Chief Financial Officer

Leadership communications in public filings and investor materials consistently emphasized clinical validation, regulatory engagement, intellectual property development, and operational discipline as central elements of the company’s strategy. Governance disclosures were primarily documented through SEC filings, including annual reports, quarterly reports, and restructuring-related disclosures.